Intermune Inc., of Brisbane, Calif., reported Esbriet (pirfenidone), for the treatment of idiopathic pulmonary fibrosis (IPF) in adults in Europe and Canada, revenue in the second quarter of 2014 was $35.7 million, compared with $14.4 million in the second quarter of 2013.